2025 Texas sessionsRegular and both called sessions have ended. This index covers House and Senate bills, not resolutions. Statuses come from official reports.

2025 · Regular session · House bill

HB4783

Read bill highlights ↓

Official caption: Relating to a report on governmental opioid antagonist programs to reverse and prevent opioid overdoses.

Signed by governorSource-checked explanation published

Official report lists House author(s): VanDeaver. This does not identify sponsors or amendment drafters.

Report an error ↗

Bill explanation published · Version and amendment review scope is stated below · Individual amendment records may not be separately annotated.

Bill highlights

Selected points from the published explanation. Follow each point to its source-linked context; conditions and limits may matter.

HB4783 requires the Health and Human Services Commission to evaluate Texas distribution of opioid antagonists—drugs that block or inhibit opioid effects—and report to the governor, lieutenant governor and House speaker by October 1 of each even-numbered year.
The report must assess the needs of state-agency and university programs; set a statewide “saturation goal,” meaning a target for adequate availability; explain the data and methods used to estimate supply shortages; and provide a communications plan for areas at higher overdose risk.
The commission must consult every state agency and higher-education institution receiving funding or other resources for opioid-antagonist distribution.

Read the full explanation ↓

What does it do?

HB4783 requires the Health and Human Services Commission to evaluate Texas distribution of opioid antagonists—drugs that block or inhibit opioid effects—and report to the governor, lieutenant governor and House speaker by October 1 of each even-numbered year. It took effect September 1, 2025, making October 1, 2026, the first recurring deadline after enactment. This briefing describes the legal duty, not a finding that a report has been delivered. Final law

The report must assess the needs of state-agency and university programs; set a statewide “saturation goal,” meaning a target for adequate availability; explain the data and methods used to estimate supply shortages; and provide a communications plan for areas at higher overdose risk. It must also describe state and federal appropriations, list publicly funded purchase and distribution programs, establish distribution strategies, and recommend improvements for high-risk groups, including school-aged children, pregnant and postpartum women, and rural residents.

The commission must consult every state agency and higher-education institution receiving funding or other resources for opioid-antagonist distribution. The bill adds an evaluation and planning duty to existing programs. It does not itself appropriate money, require every school or business to stock medication, or guarantee any individual a supply. Existing program and new reporting provision

What changed along the way?

The introduced bill and House versions focused the needs assessment and appropriation review on the specific program in Health and Safety Code Section 461A.059. The Senate committee substitute broadened those parts to governmental programs, including programs established by state agencies and universities. It also removed the express requirement to consult political subdivisions and removed the restriction tying consultation to resources received under Section 461A.059. The final consultation requirement covers state agencies and higher-education institutions receiving distribution resources more generally.

The Senate substitute became the final text after House concurrence. There are no separately numbered floor amendments in the official index; the substantive change was a committee substitute, despite the history’s general reference to “Senate amendments.” The governor signed the bill June 20, 2025. History · Text versions · Amendment index

For the full amendment record, open the official amendment index.

Official bill versions

Compare the published text versions in the official text index. A change is not attributed to a specific amendment here without a verified record.

Who could benefit—and who could bear the costs?

People at risk of opioid overdose, responders and program managers could benefit if a statewide inventory reveals gaps and leads to better distribution. Those benefits depend on the quality of the assessment and subsequent action; a reporting requirement alone does not establish that overdoses will fall. State agencies and universities must contribute information and coordination time.

The final available fiscal note anticipates no significant state or local-government fiscal impact and assumes implementation costs can be absorbed with existing resources. It does not estimate a specific number of lives saved, new medication purchases or program savings.

Official sources

Catalog report retrieved 2026-10-25. Check the official record for corrections or later changes.